{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T08:03:01Z","timestamp":1771920181841,"version":"3.50.1"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objectives<\/jats:title>\n<jats:p>Several prospective trials had been reported on chemotherapy with or without antiangiogenic agents in patients with advanced malignant pleural mesothelioma (MPM), with diverse results. We performed this systematic review and meta-analysis to evaluate the efficacy and safety of the combination regimen.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We systematically identified trials in several databases, including MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, ASCO Abstracts and ESMO Abstracts. All the randomized controlled trials (RCTs) about chemotherapy combined with antiangiogenic agents in advanced MPM were identified. Overall survival (OS) was the primary outcome, while progression-free survival (PFS), overall response rate (ORR) and serious toxicities were the secondary outcomes. Review Manager 5.3 was used to perform the statistical analyses. Stata 12.0 was used to assess the publication bias of egger\u2019s test.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>5 randomized controlled trials containing 1250 patients were finally included in this analysis. Statistical analyses showed that the addition of antiangiogenic agents to chemotherapy could prolong OS [HR 0.79 (0.71\u20130.89), p&lt;0.0001] and PFS [HR 0.75 (0.68\u20130.84), p&lt;0.00001] in advanced MPM, especially in the epithelioid subgroup, with a tolerable toxicity profile. No significant difference was found in the analysis of ORR [HR 1.13 (0.95\u20131.35), p = 0.18]. Heterogeneity was found in the analyses of PFS and ORR, which might be caused by the limitation in uniform evaluation of tumor response.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The combination of antiangiogenic agents with chemotherapy showed superior over chemotherapy alone in patients with advanced MPM. More prospective trials should be warranted to identify patients who would most likely benefit from the combination regimen.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0295745","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T18:36:38Z","timestamp":1703183798000},"page":"e0295745","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety profile of combining antiangiogenic agents with chemotherapy in patients with advanced malignant pleural mesothelioma: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1371","volume":"18","author":[{"given":"Wei","family":"Tian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daidi","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8108-1508","authenticated-orcid":true,"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"key":"pone.0295745.ref001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"pone.0295745.ref002","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"TA Yap","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"pone.0295745.ref003","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2606)","volume":"33","author":"S Popat","year":"2022","journal-title":"Ann Oncol"},{"key":"pone.0295745.ref004","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"NJ Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"pone.0295745.ref005","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1634\/theoncologist.2014-0465","article-title":"Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor","volume":"20","author":"Y Zhao","year":"2015","journal-title":"Oncologist"},{"key":"pone.0295745.ref006","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/JTO.0b013e3181d2f008","article-title":"Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma","volume":"5","author":"A Yasumitsu","year":"2010","journal-title":"J Thorac Oncol"},{"key":"pone.0295745.ref007","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0","article-title":"Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression","volume":"189","author":"S Kumar-Singh","year":"1999","journal-title":"J Pathol"},{"key":"pone.0295745.ref008","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1164\/rccm.201404-0658OC","article-title":"Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy","volume":"190","author":"K Schelch","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"pone.0295745.ref009","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1159\/000176386","article-title":"Mesothelioma cell proliferation through autocrine activation of PDGF-\u03b2\u03b2 receptor","volume":"29","author":"M Honda","year":"2012","journal-title":"Cell Physiol Biochem"},{"key":"pone.0295745.ref010","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/JTO.0b013e318229586e","article-title":"Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509","volume":"6","author":"LL Garland","year":"2011","journal-title":"J Thorac Oncol"},{"key":"pone.0295745.ref011","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/JTO.0b013e31828c2b26","article-title":"Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy","volume":"8","author":"S Papa","year":"2013","journal-title":"J Thorac Oncol"},{"key":"pone.0295745.ref012","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/JTO.0b013e31825f22ee","article-title":"A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma","volume":"7","author":"AK Nowak","year":"2012","journal-title":"J Thorac Oncol"},{"key":"pone.0295745.ref013","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"G Zalcman","year":"2016","journal-title":"Lancet"},{"key":"pone.0295745.ref014","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"JF Tierney","year":"2007","journal-title":"Trials"},{"key":"pone.0295745.ref015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"P Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"pone.0295745.ref016","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S2213-2600(19)30139-0","article-title":"Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"7","author":"GV Scagliotti","year":"2019","journal-title":"Lancet Respir Med"},{"key":"pone.0295745.ref017","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1200\/JCO.19.00269","article-title":"Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Na\u00efve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905)","volume":"37","author":"AS Tsao","year":"2019","journal-title":"J Clin Oncol"},{"key":"pone.0295745.ref018","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S1470-2045(21)00404-6","article-title":"Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"22","author":"C Pinto","year":"2021","journal-title":"Lancet Oncol"},{"key":"pone.0295745.ref019","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2017.72.9012","article-title":"Nintedanib Plus Pemetrexed\/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial","volume":"35","author":"F Grosso","year":"2017","journal-title":"J Clin Oncol"},{"key":"pone.0295745.ref020","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"MJ Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"pone.0295745.ref021","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1002\/ijc.27441","article-title":"Tumor-platelet interaction in solid tumors","volume":"130","author":"D Buergy","year":"2012","journal-title":"Int J Cancer"},{"key":"pone.0295745.ref022","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/JTO.0000000000000181","article-title":"Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee","volume":"9","author":"HI Pass","year":"2014","journal-title":"J Thorac Oncol"},{"key":"pone.0295745.ref023","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/path.824","article-title":"Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma","volume":"193","author":"L Strizzi","year":"2001","journal-title":"J Pathol"},{"key":"pone.0295745.ref024","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.jtho.2018.08.2036","article-title":"Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation","volume":"13","author":"AS Tsao","year":"2018","journal-title":"J Thorac Oncol"},{"key":"pone.0295745.ref025","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"A Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"pone.0295745.ref026","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"P Baas","year":"2021","journal-title":"Lancet"},{"key":"pone.0295745.ref027","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"D Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"pone.0295745.ref028","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC","volume":"378","author":"MA Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"pone.0295745.ref029","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1186\/s12885-018-4720-z","article-title":"Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma","volume":"18","author":"MC Kim","year":"2018","journal-title":"BMC Cancer"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0295745","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T18:37:11Z","timestamp":1703183831000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0295745"}},"subtitle":[],"editor":[{"given":"Jun Hyeok","family":"Lim","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":29,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0295745","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]}}}